Ablexis' Pharmaceutical Consortium
This article was originally published in Start Up
Executive Summary
Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.
You may also be interested in...
Inimitable Ablexis Delivers Mice To Partners, Multiples To Investors
Antibody platform play Ablexis has successfully built its technology, fulfilled a commitment to its pharmaceutical partners, triumphed in a lawsuit brought by one of biotech’s big boys, and lined the pockets of its investors. Surprisingly, it has no imitators.
Forma To Play To Its Strengths WIth Genentech Deal
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
Forma To Play To Its Strengths WIth Genentech Deal
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.